. Author manuscript; available in PMC: 2018 Jul 15.

Published in final edited form as: Bioorg Med Chem Lett. 2017 May 16;27(14):3107–3110. doi: 10.1016/j.bmcl.2017.05.038

Table 1.

Antiproliferative activities (GI₅₀, μM) of compounds 2 and 4 in breast cancer cells.^a

-R	MDA-MB-231		MDA-MB-468

	Series 2^b	Series 4	Series 2^b	Series 4
	1.60 ± 0.51	0.20 ± 0.17	0.44 ± 0.14	0.088 ± 0.026
Me (b)	27.17 ± 11.40	>100^c	53.54 ± 29.54	>100^c
Et (c)	21.43 ± 9.86	72.84 ± 5.64	24.41 ± 3.33	28.30 ± 7.05
n-Pr (d)	25.52 ± 9.93	3.46 ± 1.46	27.37 ± 4.52	2.02 ± 1.10
i-Pr (e)	39.66 ± 22.46	>100^c	29.80 ± 8.41	>100^c
t-Bu (f)	N/A^d	>100^c	N/A^d	>100^c

The antiproliferative activities of the compounds were assessed using the MTT assay. The cells were incubated with different concentrations of the drugs for 72 h. Then the number of viable cells was quantified by the MTT reagent. The GI₅₀s, presented as mean ± SD (standard deviation), were calculated from the corresponding dose-response curves in Prism 5.0 using non-linear regression analysis. The SD was calculated from at least two independent measurements.

The GI₅₀s for series 2 were from ref¹⁰.

The GI₅₀ was not reached at the highest tested concentration (100 μM).

This compound was not assessed.